Author name: Emily Crane

Emily Crane is a writer, producer, and editor who has covered politics, health, business, and finance for publications like The Atlantic. She's also the host of the All Work All Play Podcast. She graduated from Northwestern University's Medill School of Journalism with a focus on investigative reporting and data visualization.

Avatar of Emily Crane

Nonprofit launches mobile app to address industry mental health crisis

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. The ABC Cares Foundation has created a mobile app designed to address the mental health challenges faced by construction workers. The charitable arm of Associated Builders and Contractors’ Florida East Coast chapter launched the app on Monday […]

Nonprofit launches mobile app to address industry mental health crisis Read More »

108001061 1719945038626 gettyimages 2126120259 ZEPBOUND PATIENT SHORTAGES

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly on Thursday reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company’s quarterly earnings topped Wall Street estimates, but sales fell just short as Mounjaro saw lower realized prices. Zepbound and Mounjaro have now underperformed expectations for two straight

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short Read More »

108086195 1736866540584 gettyimages 2184000208 SINGAPORE ELI LILLY

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, a few months earlier than anticipated.  The company expects to provide results from a 68-week study in people with obesity and osteoarthritis of the knee in 2025, according to fourth-quarter earnings

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected Read More »

107092998 16585193832022 07 22t193800z 1350941788 rc24hv9xnyxq rtrmadp 0 health cancer

Bristol Myers' stock decline in response to weak guidance is a gift to investors

Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per

Bristol Myers' stock decline in response to weak guidance is a gift to investors Read More »

6BHSIXBYDREVTPO3WXE5MR7CU4

New study confirms novel live probiotic effective in improving skin health

A recent study published in the International Journal of Cosmetic Science has shown that a topical serum containing the live probiotic Micrococcus luteus strain Q24, known as BLIS Q24, can significantly improve multiple skin health parameters. To learn more about the study and its key takeaways for cosmetics and personal care product manufacturers and suppliers,

New study confirms novel live probiotic effective in improving skin health Read More »

LWN3M3CLARDDZHEWD4HV7G5LKM

Adaptive Beauty: Meet the new standard of inclusivity in personal care

Global beauty insight platform BEAUTYSTREAMS has identified Adaptive Beauty as one of the biggest trends redefining inclusivity in 2025. Centering on “how developments that make beauty more accessible for specific demographics can benefit everyone,” Eleonora Mazzilli, Trend Localization & Business Development Director, North America, told CosmeticsDesign, Adaptive Beauty means crafting products and services to open

Adaptive Beauty: Meet the new standard of inclusivity in personal care Read More »

february 2025 nafa ride and drive 1200x630 s

NAFA Unveils New EV Test Track and Ride & Drive Experience Return at I&E 2025

The Ride & Drive Experience returns for I&E 2025, allowing attendees to get behind the wheel of electric and alternative fuel vehicles in a real-world setting. Photo: Ross Stewart / Stewart Digital Media NAFA Fleet Management Association (NAFA) recently announced the addition of a new Indoor EV (electric vehicle) Test Track, alongside the return

NAFA Unveils New EV Test Track and Ride & Drive Experience Return at I&E 2025 Read More »

107405227 1713892869713 gettyimages 1880595297 BRISTOL MYERS SQUIBB

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance

Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth.  Bristol Myers said savings will be driven by organizational changes and efforts to streamline operations, and will allow the company to invest in new science

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance Read More »

Scroll to Top